MODEL Trademark

Trademark Overview


On Friday, July 28, 2023, a trademark application was filed for MODEL with the United States Patent and Trademark Office. The USPTO has given the MODEL trademark a serial number of 98106330. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Wednesday, June 12, 2024. This trademark is owned by Aliada Therapeutics, Inc.. The MODEL trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

pharmaceuticals and therapeutic pharmaceuticals for the treatment of neurological conditions; pharmaceuticals and therapeutic pharmaceuticals for the treatment and prevention of immunological conditions; pharmaceuticals and therapeutic pharmaceuticals for the treatment of cancer; pharmaceuticals and therapeutic pharmaceuticals for the treatment and prevention of ophthalmic conditions

biotechnology platform in the nature of structure of proteins and antibodies for use in the treatment of neurological conditions and cancer, for use in the treatment and prevention of immunological conditions and ophthalmic conditions; research and development of therapeutics for others
model

General Information


Serial Number98106330
Word MarkMODEL
Filing DateFriday, July 28, 2023
Status641 - NON-FINAL ACTION - MAILED
Status DateWednesday, June 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and Servicespharmaceuticals and therapeutic pharmaceuticals for the treatment of neurological conditions; pharmaceuticals and therapeutic pharmaceuticals for the treatment and prevention of immunological conditions; pharmaceuticals and therapeutic pharmaceuticals for the treatment of cancer; pharmaceuticals and therapeutic pharmaceuticals for the treatment and prevention of ophthalmic conditions
Goods and Servicesbiotechnology platform in the nature of structure of proteins and antibodies for use in the treatment of neurological conditions and cancer, for use in the treatment and prevention of immunological conditions and ophthalmic conditions; research and development of therapeutics for others

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, August 28, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, August 28, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAliada Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBoston, MA 02116

Trademark Events


Event DateEvent Description
Tuesday, August 1, 2023NEW APPLICATION ENTERED
Monday, August 28, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, March 29, 2024NON-FINAL ACTION WRITTEN
Friday, March 29, 2024NON-FINAL ACTION E-MAILED
Friday, March 29, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 30, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 29, 2024ASSIGNED TO EXAMINER
Tuesday, April 30, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, April 30, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, June 12, 2024NON-FINAL ACTION WRITTEN
Wednesday, June 12, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, June 12, 2024NON-FINAL ACTION E-MAILED